UBS Group
UTHR icon

UBS Group’s United Therapeutics UTHR Stock Holding History

UBS Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-20,700
Closed -$2.34M – 8285
2018
Q2 		$2.34M Buy
+20,700
New +$2.28M ﹤0.01% 3026
2015
Q3 		– Sell
-10,800
Closed -$1.88M – 8645
2015
Q2 		$1.88M Buy
+10,800
New +$1.94M ﹤0.01% 3038

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

UBS Group's UTHR Position: Q2 2026 in Review

UBS Group reduced its United Therapeutics (UTHR) stake by 6.8% in Q2 2026, selling an estimated $9.07M and leaving 220,616 shares worth $120M. The position accounts for 0.02% of the portfolio, ranked #1000.

UBS Group first reported a position in UTHR in Q4 2014 and has held it in 47 quarters since. The position peaked at $140M in Q1 2026. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • UBS Group held 220,616 shares of United Therapeutics worth $120M as of Q2 2026.
  • UBS Group sold 16,113 United Therapeutics shares in Q2 2026, an estimated $9.07M.
  • United Therapeutics made up 0.02% of UBS Group's portfolio in Q2 2026, its #1000 holding.
  • UBS Group first reported a position in United Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's United Therapeutics position peaked at $140M in Q1 2026.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.